Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35657079

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Jun 30
First author
Wang ML

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Aug;19(8):494. doi: 10.1038/s41571-022-00658-6.
    note
    Source null
    related pmid
    35750854
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 Sep 22;387(12):1146-1147. doi: 10.1056/NEJMc2209904.
    note
    Source null
    related pmid
    36130007
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 Sep 22;387(12):1147. doi: 10.1056/NEJMc2209904.
    note
    Source null
    related pmid
    36130008
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 Sep 22;387(12):1147-1148. doi: 10.1056/NEJMc2209904.
    note
    Source null
    related pmid
    36130009
    relationship
    Comment in

Authors and identifiers

  1. name
    Wang ML
    type
    Author
  2. name
    Jurczak W
    type
    Author
  3. name
    Jerkeman M
    type
    Author
  4. name
    Trotman J
    type
    Author
  5. name
    Zinzani PL
    type
    Author
  6. name
    Belada D
    type
    Author
  7. name
    Boccomini C
    type
    Author
  8. name
    Flinn IW
    type
    Author
  9. name
    Giri P
    type
    Author
  10. name
    Goy A
    type
    Author
  11. name
    Hamlin PA
    type
    Author
  12. name
    Hermine O
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wang ML
    type
    Author
  2. name
    Jurczak W
    type
    Author
  3. name
    Jerkeman M
    type
    Author
  4. name
    Trotman J
    type
    Author
  5. name
    Zinzani PL
    type
    Author
  6. name
    Belada D
    type
    Author
  7. name
    Boccomini C
    type
    Author
  8. name
    Flinn IW
    type
    Author
  9. name
    Giri P
    type
    Author
  10. name
    Goy A
    type
    Author
  11. name
    Hamlin PA
    type
    Author
  12. name
    Hermine O
    type
    Author
bibliography ids
  1. nci-bib-f580d41e39e4201b6c41871c
book metadata
content sha256
af3311c14d187b7b4ae7d250dee794015b089addb90a3b9fbf7d61fd147e2976
document type
citation
dois
  1. 10.1056/NEJMoa2201817
electronic publication date
display
2022 Jun 3
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35657079
immutable id
pubmed:35657079@af3311c14d187b7b4ae7d250dee794015b089addb90a3b9fbf7d61fd147e2976
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
26
name
The New England journal of medicine
nlm unique id
0255562
pages
2482-2494
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Aug;19(8):494. doi: 10.1038/s41571-022-00658-6.
    note
    Source null
    related pmid
    35750854
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 Sep 22;387(12):1146-1147. doi: 10.1056/NEJMc2209904.
    note
    Source null
    related pmid
    36130007
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 Sep 22;387(12):1147. doi: 10.1056/NEJMc2209904.
    note
    Source null
    related pmid
    36130008
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 Sep 22;387(12):1147-1148. doi: 10.1056/NEJMc2209904.
    note
    Source null
    related pmid
    36130009
    relationship
    Comment in
outcomes validated
false
pmid
35657079
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
da034f982f91df054f0049f79d33652f911771ba9d5f870741df2ef9b1e58d10
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Jun 30
precision
day
year
2022
publication types
  1. Journal Article
  2. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35657079/
title
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

Preserved source evidence · Not medical advice